

Now Available in 20 mg Strength

ESOGRESS-20

Esomeprazole Gastro Resistant Tablets 20 mg

ESOGRESS-40/D/L

Esomeprazole Gastro Resistant Tablets 40 mg/

Esomeprazole(Enteric Coated) 40 mg with Domperidone 30 mg Sustained Release Capsules/

Esomeprazole(Enteric Coated) 40 mg with Levosulpiride Sustained Release 75 mg Capsules



Now Available in 20 mg Strength

ESOGRESS-20

Esomeprazole Gastro Resistant Tablets 20 mg

ESOGRESS-D

Esomeprazole EC 40 mg with Domperidone 30 mg Sustained Release Capsules

ESOGRESS-40

Esomeprazole Gastro Resistant Tablets 40 mg

ESOGRESS-L

Esomeprazole EC 40 mg with Levosulpiride Sustained Release 75 mg Capsules



BACKGROUND:

Gastroesophageal reflux disease (GERD) and Dyspepsia syndrome are prevalent in the community worldwide. In an individual, GERD and dyspepsia may occur simultaneously and therefore they are hardly discriminated. It is estimated that 25% of the community has symptoms of dyspepsia syndrome. The global pooled prevalence of GERD is 13.98% and varied greatly according to region and country and the Prevalence of dyspepsia is about 20-30%. PPI alone or in combination with a prokinetic agent is effective in improving the quality of life of patients suffering from diseases associated with acid reflux.






DESCRIPTION:

Esogress-20/40 contains Esomeprazole 20/40 mg Gastro-resistant Tablets with Sodium Bicarbonate Buffer.

Esogress-D contains Esomeprazole EC 40 mg with Domperidone 30 mg Sustained-Release Capsules.

Esogress-L contains Esomeprazole EC 40 mg with Levosulpiride Sustained Release 75 mg Capsules.

INDICATION:

-  GERD
-  NAB (Nocturnal Acid Breakthrough)
-  Diabetic Gastroparesis
-  Functional Dyspepsia
-  Gastritis

MECHANISM OF ACTION:

Esomeprazole is the S-enantiomer of omeprazole, specifically act on proton pump inhibitor, suppressing gastric acid secretion by specific inhibition of the H⁺/K⁺ ATPase in the gastric parietal cell and blocking the final step in acid production, resulting in reduced gastric acidity.

Domperidone has strong affinities for the D2 and D3 dopamine receptors, found in the chemoreceptor trigger zone, located just outside the blood brain barrier. It facilitates gastric emptying and decreases small bowel transit time by increasing esophageal and gastric peristalsis and by lowering esophageal sphincter pressure.

Levosulpiride is a sulpiride isomer that exerts its prokinetic action through a dual mechanism, as a D2 dopamine receptor antagonist and as a serotonin 5HT₄ receptor agonist.

KEY FEATURES:

Esomeprazole is effective in maintaining intragastric pH greater than equal to 4 compared to other PPI.¹

Domperidone is a unique gastropromkinetic and antiemetic drug, it does not cross the blood-brain barrier and therefore has fewer CNS side effects.²

Levosulpiride has better tolerability than Cisapride and Metoclopramide.³

Unlike cisapride, levosulpiride is devoid of serious cardiovascular adverse effects.³

Sodium Bicarbonate buffered oral Esomeprazole shows a faster onset of action when compared with Enteric-coated Esomeprazole Tablet.⁴

PRESENTATION:

Esogress-20/40 available as a strip of 10 Tablets.

Esogress-D/L available as a strip of 10 Capsules.

References:

1. *Therapeutics and Clinical Risk Management* 2007;3:653-663
2. *Am J Gastroenterol* 1999 May;94:1230-4.
3. *J Fam Med.* 2015;2: 1034.
4. *Drug Design, Development and therapy* 2019;13,3151-3159

La Renon Healthcare Private Limited

207-208 ISCON Elegance | Circle P | Prahlad Nagar Cross Roads | S.G.Highway | Ahmedabad - 380015 | Gujarat | India.
Phone: +91-79-6616-8998 | 2693-6656 | Fax: +91-79-6616-8998 E-Mail: info@larenon.com | www.larenon.com